ProCE Banner Activity

APHINITY: Interim OS Analysis of Adjuvant CT Plus Trastuzumab With vs Without Pertuzumab for Patients With HER2+ EBC

Slideset Download
Conference Coverage
Continued significant improvement in invasive disease–free survival but not OS evident with addition of pertuzumab to adjuvant chemotherapy plus trastuzumab in patients with HER2+ EBC with 6-year follow-up.

Released: December 16, 2019

Expiration: December 14, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen